SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling.

Structure-activity relationships of a series of bis-arylic compounds, investigated as 5-HT(7)R ligands, are reported. The main structural modifications involved a central aryl moiety (phenyl, pyridine, diazine, triazine) and the nature and position of an amine-containing aliphatic chain. The affinity of the synthesized compounds (26 nM-10 microM) was systematically correlated with other previously reported series of bis-arylic ligands and rationalized by a ligand-based pharmacophore approach.

[1]  Beata Duszyńska,et al.  The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines. , 2007, Bioorganic & medicinal chemistry.

[2]  D. Yamazaki,et al.  Pyrimidine-core extended pi-systems: general synthesis and interesting fluorescent properties. , 2004, Journal of the American Chemical Society.

[3]  S. Rosqvist,et al.  Novel 3-aminochromans as potential pharmacological tools for the serotonin 5-HT(7) receptor. , 2005, Bioorganic & medicinal chemistry letters.

[4]  J. Macor,et al.  Further intramolecular reactions of 1,2,4-triazines. Synthesis of furo[2,3-b]pyridines and dihydropyrano[2,3-b]pyridines , 1986 .

[5]  J. Lavandera,et al.  First pharmacophoric hypothesis for 5-HT7 antagonism. , 2000, Bioorganic & medicinal chemistry letters.

[6]  H. Vaudry,et al.  Novel aminoethylbiphenyls as 5-HT7 receptor ligands. , 2007, Bioorganic & medicinal chemistry letters.

[7]  T. Blackburn,et al.  The medical benefit of 5-HT research , 2002, Pharmacology Biochemistry and Behavior.

[8]  N. Mohell,et al.  Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists. , 2004, Journal of medicinal chemistry.

[9]  Anne W. Schmidt,et al.  Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides. , 2004, Journal of medicinal chemistry.

[10]  Anne W. Schmidt,et al.  Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site. , 2003, Journal of medicinal chemistry.

[11]  L. Salerno,et al.  5-HT7 receptor ligands: recent developments and potential therapeutic applications. , 2007, Mini reviews in medicinal chemistry.

[12]  M. Leopoldo.  Serotonin(7) receptors (5-HT(7)Rs) and their ligands. , 2004, Current medicinal chemistry.

[13]  M. Beer,et al.  Thiazoles and thiopyridines: novel series of high affinity h5HT(7) ligands. , 2004, Bioorganic & medicinal chemistry letters.

[14]  L. Pardo,et al.  Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives. , 2003, Journal of medicinal chemistry.

[15]  G. Guillaumet,et al.  Synthesis of 3‐Amino‐8‐azachromans and 3‐Amino‐7‐azabenzofurans via Inverse Electron Demand Diels–Alder Reaction , 2009 .

[16]  Mateusz Nowak,et al.  Receptor-based pharmacophores for serotonin 5-HT7R antagonists-implications to selectivity. , 2006, Journal of medicinal chemistry.